May 20 , 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, is pleased to announce that the Company has closed the acquisitions of the assets of Laevoroc Immunology AG (“ Laevoroc Immunology ”) and Laevoroc Chemotherapy AG (“... Read More

Toronto, Ontario – TheNewswire – April 24, 2025 - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today announced the appointments of Veronika Kandziora as Chief Operating Officer ( “COO” ) and Jessica Kourniaktis, DPhil , as Director of Communications of the... Read More

April 10, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today announced the appointment of Thomas Mehrling, MD, PhD as Chief Executive Officer ( “CEO” ) of the Company. A sharpening of Helix’s leadership structure,... Read More

April 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announces that, subject to regulatory approval, it has engaged the services of Independent Trading Group ( "ITG" ) to provide market-making services in accordance with... Read More

March 26, 2025 - (Toronto, Ontario) – TheNewswire - Helix BioPharma Corp . (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, is pleased to announce the voting results from the Annual General and Special Meeting of its Shareholders (the “ Meeting ”) held on Wednesday, March 26, 2025. A total... Read More

March 18, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announces the filing of the Company’s unaudited interim financial statements as of and for the three and six month periods ended January 31, 2025 (the “Financial... Read More

March 11, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, is pleased to announce an upcoming poster presentation highlighting the effects of Tumour Defence Breaker™, L-DOS47, in CEACAM6-expressing head and neck cancer cells... Read More

March 6, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, is pleased to announce the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix’s commitment to... Read More

February 2 4 , 2025 - (Toronto, Ontario) – TheNewswire – Helix BioPharma Corp . (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announces that its Annual General and Special Meeting (the “Meeting”) for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended... Read More

January 9, 2025 - (Toronto, Ontario) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies in immune-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce that it has closed the private placement of 4,000,000 common shares of the Company (“Common... Read More

Toronto, Ontario – TheNewswire – December 11, 2024 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immune-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce the appointment of James B. Murphy as Chief Financial Officer ( “CFO” )... Read More

December 6, 2024, (Toronto, Ontario) – TheNewswire – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immune-oncology, based on its proprietary technological CEACAM6 platform, DOS47, announces that, further to its news releases dated November 29, 2024 and December 2, 2024,... Read More

December 2, 2024 – TheNewswire – (Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage biopharmaceutical company developing novel therapies in immune-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce it has entered into an asset purchase agreement dated November 30, 2024 (the “Agreement” )... Read More

November 29, 2024 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immune-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce that it has entered into an asset purchase agreement dated November 28,... Read More

(Toronto, Ontario) – TheNewswire – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immuno-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce the issuance of U.S. Patent No. 11931422. U.S. Patent No. 11931422, entitled... Read More

November 13, 2024 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immuno-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce that the Company has entered into a non-binding letter of intent (LOI) to... Read More

November 11, 2024 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immuno-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce that the Company attended the 15th World ADC San Diego from 4–7 November... Read More

November 8 , 2024 – TheNewswire - (Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immuno-oncology, based on its proprietary technological CEACAM6 platform, DOS47, announces the resignation of the Company’s Chief Financial Officer (“CFO”) and Corporate... Read More

January 18, 2024 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company’s annual and general meeting of shareholders held on January 18, 2024 (the “Meeting”). There were 34... Read More

Toronto, Ontario – TheNewswire – December 14, 2023 – Helix BioPharma Corp. (TSX:HBP), (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal... Read More

Toronto, Ontario - TheNewswire - October 27, 2023 - Helix BioPharma Corp. (TSX:HBP) , (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the 2023 fiscal year ended July 31, 2023. OVERVIEW The Company reported a net loss and total comprehensive loss of... Read More

Toronto, Ontario - TheNewswire - October 10, 2023 - Helix BioPharma Corp. (TSX:HBP) (“ Helix ” or the “ Company ”), an immune-oncology antibody-drug-conjugate company developing an innovative drug platform for the treatment of cancer, announced today that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR-NCI-EORTC International Conference on Molecular... Read More

Toronto, Ontario - TheNewswire - August 22, 2023 - Helix BioPharma Corp. (TSX:HBP) (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed the first tranche of private placement financing for gross proceeds of CAD $2,998,000 from the issuance of 16,655,557... Read More

Toronto, Ontario – TheNewswire – June 14, 2023 - Helix BioPharma Corp . (TSX:HBP), (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal 2023 third quarter results for the period ending April 30, 2023. OVERVIEW The Company reported a net loss... Read More

Toronto, ON - TheNewswire - March 15, 2023 - Helix BioPharma Corp. (TSX:HBP) , (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal 2023 second quarter results for the period ending January 31, 2023. OVERVIEW The Company reported a net loss... Read More

Toronto, Ontario – Thenewswire – December 14, 2022 – Helix BioPharma Corp. (TSX:HBP), (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal... Read More

Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced changes in its board of directors (the "Board") and management. The Company is pleased to announce that Mr. Jacek Antas has been appointed as the Company’s CEO to replace Mr. Artur Gabor with... Read More